Botanix Pharmaceuticals (ASX:BOT) Acquires US FDA Consent For BTX 1801 Development

  • November 12, 2020 04:04 PM AEDT
  • Team Kalkine
    Team Kalkine
    admin Team Kalkine
    16957 Posts

    Team Kalkine comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different markets with...

Botanix Pharmaceuticals Limited (ASX:BOT) has responsibly accomplished a novel drug meeting with the US Food and Drug Administration department of Infectious Diseases.

The meeting evaluated the prospective of starting out a clinical development of the BOT’s antimicrobial drug BTX 1801 for blocking surgical site infections in the US.   

The meeting also aided the company to obtain feedback from the FDA on the plan of BTX 1801 drug development.

It should be noted that in April 2020, BTX 1801 was given a Qualified Infectious Disease Product (QIDP) label. Any product with QIDP eminence gets next five years of regulatory superiority.     

Botanix’s BTX 1801 is an artificial cannabidiol gel that is made to reduce post-surgical infections.

Meanwhile, the BOT stock was trading at $0.105 with a market capitalistaion of $102.13 million at 03:02 PM AEDT.



The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK